LYVE1 and neoplasm: Even more robust was the significant overexpression of PDPN, LYVE-1 and SLP-76 (p < 0.01) when gene expression fold changes in the 6 LVI+/Ln+ MIBC patients (Pt 6, 7, 10, 12, 18, 20) showing tumor progression and in the 11 LVI-/Ln- NMIBC patients (Pt 1, 3, 4, 5, 9, 11, 16, 17, 21, 22, 23) without progression were compared (Figure 1C, Table 2).